Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2012

View Archived Issues

Merck & Co. presents new phosphodiesterase 10A inhibitors

Novel compounds for cancer patented

Photoreceptor-directed gene therapy shows promise to treat X-linked retinitis pigmentosa

New clinical results presented on Ad3-hTERT-E1A

IND cleared for phase I study of peptide to prevent dental caries

Shionogi divulges new treatments for Alzheimer's disease

ImmunoGen reports novel antibodies and immunoconjugates

Researchers at Glenmark Pharmaceuticals design new MPGES-1 inhibitors

Ensemble Therapeutics announces new collaboration

Lu-AE-58054 study meets primary endpoint

Andromeda peptide product receives FDA orphan drug status

New therapeutic approach to respiratory allergy presented

Acacia Pharma announces encouraging clinical results on APD-421

NeuroSearch reports on multiple-ascending-dose Huntexil trial

Oncos Therapeutics begins phase I study of oncolytic adenovirus

First-in-human trial of Bionor's second therapeutic HIV vaccine set to launch

Cytotoxic T lymphocytes expressing Epstein-Barr virus antigen administered to patients with lymphoma

Medivir cathepsin K inhibitor enters the clinic

Nuvo Research and Paladin Labs enter Canadian license agreement

ValiRx reports preclinical data on VAL-201

Janssen receives complete response letter regarding new Prezista tablet

FDA accepts filing of NDA for Kynamro

BMS forms international immuno-oncology collaboration with academic institutions

Advaxis completes enrollment in ADXS-HPV study

FDA validates NDA for Sitavig

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...